Collegium Q2 Revenue Hits $199.9M, JORNAY PM Surges 41%, Raises AZSTARYS Outlook
COLL is trading near its 52-week low of $29.7 (11% above the low).
Summary
Collegium delivered Q2 net revenues of $199.9M, up 6% YoY, driven by a 41% surge in JORNAY PM to $46.1M and a partial quarter contribution of $12.9M from newly acquired AZSTARYS. The pain portfolio declined 9% to $140.9M, with Nucynta franchise down 24%, partially offset by Belbuca growth. Management raised full-year AZSTARYS revenue guidance while reaffirming JORNAY PM targets, signaling confidence in the ADHD franchise ahead of the back-to-school season. The completed AZSTARYS integration and expanded salesforce position the company for a strong second half. The conference call at 8:00 a.m. ET will provide further details on the updated outlook.
At the time of this announcement, COLL was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $29.70 to $50.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.